MEQUON, Wis.--(BUSINESS WIRE)--ENDECE Neural announced today the forthcoming presentation of new evidence that the company’s lead compound, NDC-1308, an analog of estradiol being investigated for the treatment of multiple sclerosis (MS), has gained the function to remyelinate damaged axons in animal models, but does not appear to cause the deleterious side effects commonly associated with estrogens. James G. Yarger, Ph.D., ENDECE CEO, will present these results at the BioPharm America conference to be held in Boston, Mass. from September 15-17, 2015.
Help employers find you! Check out all the jobs and post your resume.
